SCHEMBL4123867

SCHEMBL4123867

CCC1(n2nc(-c3ccsc3)c(O)c(C#N)c2=O)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 2/20 0.37
MAPK9 P45984 2/20 0.37
FLT4 P35916 1/20 0.37
CSNK2A1 P68400 1/20 0.37
DYRK1A Q13627 1/20 0.37
AURKB Q96GD4 1/20 0.37
PRKD2 Q9BZL6 1/20 0.37
ADORA1 P30542 3/20 0.36
ADORA2A P29274 2/20 0.36
ACMSD Q8TDX5 1/20 0.33
PTGES O14684 2/20 0.33
MAPK10 P53779 1/20 0.33
KDM4E B2RXH2 2/20 0.32
ALDH1A1 P00352 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
USP2 O75604 1/20 0.32
HPGD P15428 1/20 0.32
TSHR P16473 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4137561 0.87 MAPK8 (0.38) MAPK8MAPK9FLT4CSNK2A1DYRK1A
SCHEMBL4129468 0.80 MEN1 (0.39) ADORA1ADORA2AACMSDKDM4EALDH1A1
SCHEMBL4142975 0.76 ADORA1 (0.40) MAPK8MAPK9FLT4CSNK2A1DYRK1A
SCHEMBL13905617 0.75 MERTK (0.41) MAPK8MAPK9FLT4CSNK2A1DYRK1A
SCHEMBL4052051 0.74 ADORA1 (0.38) MAPK8MAPK9FLT4CSNK2A1DYRK1A
SCHEMBL4126223 0.74 GRM2 (0.40) MAPK8MAPK9FLT4CSNK2A1DYRK1A
SCHEMBL13905616 0.73 ADORA2A (0.37) MAPK8MAPK9FLT4CSNK2A1DYRK1A
SCHEMBL13905623 0.73 MERTK (0.38) MAPK8MAPK9FLT4CSNK2A1DYRK1A
SCHEMBL4137219 0.72 ADORA1 (0.45) ADORA1ADORA2APTGESKDM4EALDH1A1
SCHEMBL4135197 0.71 ADORA2A (0.37) MAPK8MAPK9FLT4CSNK2A1DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090060867-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS III AND VI IDENIX PHARMACEUTICALS, INC. (US) 2009-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090060867-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS III AND VI POLR2E, POLR2H, POLI MAPK8 2449/4885MAPK9 1946/4885FLT4 4153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.